Ibrutinib plus CD19-specific CAR T-cell therapy may benefit patients with relapsed or refractory CLL

[wmay13241]

Administration of ibrutinib beginning 2 weeks prior to leukapheresis and continuing until 3 months after CD19-specific chimeric antigen receptor T-cell therapy appeared well tolerated among patients with relapsed or refractory chronic lymphocytic leukemia, according to retrospective study results presented at ASH Annual Meeting and Exposition.

healio.com/hematology-oncol...

[pkguk2 Partner CLL Support Association]

Interesting research. Hopefully this will make CAR-T more tolerable to patients, and with fewer side-effects.